Get started
Inhibikase Therapeutics, Inc.Inhibikase Therapeutics, Inc.Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

IKT chart

Key stats

Market capitalization
‪14.18 M‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.62USD
Net income
‪−19.03 M‬USD
Revenue
‪260.50 K‬USD
Shares float
‪5.23 M‬
Beta (1Y)
1.80

About Inhibikase Therapeutics, Inc.

Sector
Health Technology
CEO
Milton H. Werner
Headquarters
Atlanta
Website
inhibikase.com
Employees (FY)
8
Founded
2008
ISIN
US45719W2052
FIGI
BBG005TP2339
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of IKT is 2.19 USD — it has increased by 0.23% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Inhibikase Therapeutics, Inc. stocks are traded under the ticker IKT.
Inhibikase Therapeutics, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Inhibikase Therapeutics, Inc. has a max estimate of 27.00 USD and a min estimate of 8.00 USD.
IKT earnings for the last quarter are −0.86 USD whereas the estimation was −1.12 USD which accounts for 23.21% surprise. Estimated earnings for the next quarter are −0.85 USD. See more details about Inhibikase Therapeutics, Inc. earnings.
Inhibikase Therapeutics, Inc. revenue for the last quarter amounts to ‪6.55 K‬ USD despite the estimated figure of ‪300.00 K‬ USD. In the next quarter revenue is expected to reach ‪200.00 K‬ USD.
Yes, you can track Inhibikase Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, IKT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Inhibikase Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
IKT reached its all-time high on Dec 23, 2020 with the price of 70.79 USD, and its all-time low was 0.79 USD and was reached on Oct 10, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 8.00 employees. See our rating of the largest employees — is Inhibikase Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Inhibikase Therapeutics, Inc. EBITDA is ‪−19.91 M‬ USD, and current EBITDA margin is ‪−7.64 K‬%. See more stats in Inhibikase Therapeutics, Inc. financial statements.